Delivery Order SPE2DB22D2206-SPE2DB25FJM87
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $36,057.84 under a firm fixed-price contract structure. The order is set to be completed by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and firm fixed pricing. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This is an unrestricted, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ocrevus 300 mg/10 mL vials, valued at $96,154.24 with a firm fixed price structure. The award is non-competitive with no set-aside designation and is scheduled for completion by October 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency Medical Supply Chain for the supply of Ocrevus 300 mg/10 mL vials. The contract is valued at $120,192.80 under a firm fixed-price arrangement with an ultimate completion date of August 25, 2025. This non-competitive delivery order was issued as a child contract against a larger vehicle, leveraging AmerisourceBergen's established relationship with federal medical procurement. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ocrevus 300 mg/10 mL vials, a pharmaceutical product used to treat multiple sclerosis. This firm fixed-price delivery order, valued at $64,452.33, is scheduled for completion by September 3, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract was awarded without a set-aside designation through competitive procurement, reflecting...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $192,308.48. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical is to be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJM87Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $72,115.74 and a firm fixed price structure. The contract is classified as a child order under a larger indefinite delivery vehicle and carries an ultimate completion date of September 11, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is executed under AmerisourceBergen's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999.999 billion and extending through December 2026. That prime contract vehicle serves as a comprehensive global pharmaceutical support program enabling the supply of an extensive range of medications and medical commodities to support military healthcare systems worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and maintains a substantial portfolio of federal contracts covering specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $72.1k | 8/20/25 |